Myths and Mysteries Surrounding Adjuvant Therapy for NMIBC - Ashish Kamat

(Length of lecture - 32 minutes)

Ashish Kamat, MD presents on the myths and mysteries surrounding adjuvant therapy for non-muscle invasive bladder cancer (NMIBC).  Dr. Kamat explains the non-homogenous characteristics and lack of uniformity in risk factors of NMIBC. He discusses study results of BCG contribution to reduction in progression of NMIBC when maintenance is used. 

For reference, PDF of slides

Additional content on NMIBC:

Emerging Therapies for BCG-Unresponsive Non-muscle Invasive Bladder Cancer- EVERYDAY UROLOGY: Full Text article

Defining and treating the spectrum of intermediate-risk NMIBC 

What To Do With BCG Refractory NMIBC When Cystectomy is Not an Option?

TURBT More Important Than Ever

AUA Guidelines: Non-Muscle Invasive Bladder Cancer

Biography:
Ashish Kamat, MD, MBBS, FACS, Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Fellowship Program Director, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Associate Director, Cancer Center, Reliance Foundation HN Hospital, Mumbai, India; Wayne B. Duddlesten Professorship in Cancer Research In Honor of Dr. Ashish Kamat, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston.